This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boeckh M, Ljungman P . How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711–5719.
Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 2013; 162: 25–39.
Solano C, Muñoz-Cobo B, Giménez E, Remigia MJ, Amat P, Clari MA et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant 2013; 48: 1010–1012.
Pérez Romero P, Blanco P, Giménez E, Solano C, Navarro D . An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virol 2015; 10: 113–134.
Solano C, de la Cámara R, Vázquez L, López J, Giménez E, Navarro D . Cytomegalovirus infection management in allogeneic stem cell transplant recipients: A National Survey in Spain. J Clin Microbiol 2015; 53: 2741–2744.
Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD . Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032–2036.
Giménez E, Muñoz-Cobo B, Solano C, Amat P, Navarro D . Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J Clin Microbiol 2014; 52: 654–656.
Bravo D, Clari MÁ, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ et al. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J Clin Microbiol 2011; 49: 2899–2904.
Clari MÁ, Bravo D, Costa E, Muñoz-Cobo B, Solano C, Remigia MJ et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn Microbiol Infect Dis 2013; 75: 207–209.
Muñoz-Cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011; 17: 1602–1611.
Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ et al. Quantification of DNA in plasma by an automated real-time PCR assay (CMV PCR Kit, Abbott) for surveillance of active cytomegalovirus infection and guidance of pre-emptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46: 3311–3318.
Hayden RT, Gu Z, Sam SS, Sun Y, Tang L, Pound S et al. Comparative evaluation of three commercial quantitative cytomegalovirus standards by use of digital and real-time PCR. J Clin Microbiol 2015; 53: 1500–1505.
Fryer JF, Heath AB, Anderson R, Minor PD . Collaborative Study Group Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. WHO ECBS Report 2010. WHO/BS/ 10: 2138. World Health Organization: Geneva, Switzerland, 2010.
Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK . American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9: 258–268.
Scrucca L, Santucci A, Aversa F . Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 2010; 45: 1388–1395.
Acknowledgements
This research was supported in part by a grant (12/01992) from FIS (Fondo de Investigaciones Sanitarias, Ministerio de Sanidad y Consumo, Spain) and by private funds from Abbott Diagnostics.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DN has received honoraria from Abbott Diagnostics for participating in several conferences. All the remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Solano, C., Giménez, E., Piñana, J. et al. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant 51, 718–721 (2016). https://doi.org/10.1038/bmt.2015.303
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.303
This article is cited by
-
Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment
Bone Marrow Transplantation (2021)
-
Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide
Bone Marrow Transplantation (2020)
-
Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes
Bone Marrow Transplantation (2019)
-
The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients
Bone Marrow Transplantation (2018)
-
Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?
Bone Marrow Transplantation (2018)